Stay updated with breaking news from Tim Goodnow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First patients have been served, launching the Nurse Practitioner Group partnership to expedite and expand access to the Eversense® E3 CGMGERMANTO...
The long-term implantable E3 CGM system now approved for commercialization in select European markets Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development
Senseonics' FDA-approved CGM has a sensor that lasts six months, a first for any CGM. Other competing solutions from Medtronic and Dexcom last anywhere between three to 10 days.
The FDA has approved extending the use of an implantable continuous glucose monitoring sensor for up to 6 months for adults with diabetes, according to a company press release. Senseonics’s Eversense E3 continuous glucose monitoring system is a fully implantable third-generation sensor that connects to a removable smart transmitter and mobile app displaying glucose values, trends and
- Real-time glucose data and alerts from the world's first and only long-term CGM system can now be remotely monitored by friends and family of Eversense users on Android and iOS operating system Senseonics